Página principal > Resultados de la búsqueda: Rizzieri, David
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
20 p, 1.9 MB Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML / Menghrajani, Kamal (Leukemia Service) ; Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center) ; Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West) ; Zhang, Mei-Jie (Medical College of Wisconsin) ; Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ; Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ; Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ; Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ; Assal, Amer (Columbia University Irving Medical Center) ; Bacher, Vera Ulrike (Bern University Hospital) ; Badawy, Sherif M. (Northwestern University Feinberg School of Medicine) ; Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center) ; Bhatt, Vijaya Raj (University of Nebraska Medical Center) ; Bredeson, Christopher (Ottawa Hospital Research Institute) ; Byrne, Michael (Vanderbilt University Medical Center) ; Castillo, Paul (UF Health Shands Children's Hospital) ; Cerny, Jan (University of Massachusetts Medical Center) ; Chhabra, Saurabh (Medical College of Wisconsin) ; Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center) ; DeFilipp, Zachariah (Massachusetts General Hospital) ; Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine) ; Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH)) ; Gale, Robert Peter (Haematology Research Centre. Department of Immunology and Inflammation. Imperial College London) ; Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System) ; Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital) ; Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ; Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center) ; Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky) ; Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH) ; Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program) ; Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute) ; Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine) ; Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University) ; Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre) ; Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center) ; Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center) ; Olsson, Richard (Centre for Clinical Research Sormland. Uppsala University) ; Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center) ; Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University) ; Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center) ; Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center) ; Seo, Sachiko (Department of Hematology and Oncology. Dokkyo Medical University) ; Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ; Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital) ; Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center) ; Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic) ; Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH) ; Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center) ; Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester) ; Kebriaei, Partow (Department of Stem Cell Transplantation. Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center) ; Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota) ; Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center) ; Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center) ; Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. [...]
2022 - 10.1182/bloodadvances.2021004881
Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847  
Registro completo - Creative Commons
2.
10 p, 1.3 MB Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission : analysis from CALGB 10403 and the CIBMTR / Wieduwilt, Matthew J. (University of California) ; Stock, Wendy (University of Chicago Medicine) ; Advani, Anjali (Cleveland Clinic) ; Luger, Selina (University of Pennsylvania Medical Center) ; Larson, Richard A. (University of Chicago Medicine) ; Tallman, Martin (Memorial Sloan Kettering Cancer Center. Leukemia Service, Department of Medicine) ; Appelbaum, Frederick (Fred Hutchinson Cancer Research Center) ; Zhang, Mei-Jie (Medical College of Wisconsin. Division of Biostatistics) ; Bo-Subait, Khalid (Medical College of Wisconsin) ; Wang, Hai-Lin (Medical College of Wisconsin) ; Bhatt, Vijaya Raj (University of Nebraska Medical Center) ; Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ; Eapen, Mary (Medical College of Wisconsin) ; Hamadani, Mehdi (Medical College of Wisconsin) ; Jamy, Omer (University of Alabama at Birmingham) ; Prestidge, Tim (Starship Children's Hospital (Auckland, Nova Zelanda)) ; Pulsipher, Michael (Children's Hospital Los Angeles Cancer) ; Ritchie, David (Peter MacCallum Cancer Centre) ; Rizzieri, David (Duke University) ; Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Sandmaier, Brenda M. (Fred Hutchinson Cancer Research Center) ; de Lima, Marcos (University Hospitals Case Medical Center) ; Kebriaei, Partow (The University of Texas MD Anderson Cancer Center) ; Litzow, Mark (Mayo Clinic.) ; Saber, Wael (Medical College of Wisconsin) ; Weisdorf, Daniel (University of Minnesota) ; Universitat Autònoma de Barcelona
Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. [...]
2021 - 10.1038/s41375-021-01213-5
Leukemia, Vol. 35 (march 2021) , p. 2076-2085  
Registro completo - Creative Commons

Vea también: autores con nombres similares
2 Rizzieri, D.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos